Advanced search

Report side effect

Report a suspected side effect or falsified product to the MHRA Yellow Card scheme.
Go to {yellow_card_logo} site
{arrow_up} Back to top

Sterile Concentrate for Cardioplegia Infusion

Active Ingredient:
potassium chloride , magnesium chloride hexahydrate , procaine hydrochloride
Company:  
Martindale Pharma, an Ethypharm Group Company See contact details
About Medicine
{medical_services}
Prescription only medicine
Healthcare Professionals (SmPC) Patient Leaflet (PIL) HCP Med Info
{arrow_left}
{arrow_right}
{healthcare_pro_orange} This information is for use by healthcare professionals
Last updated on emc: 18 Feb 2015

Quick Links

Undesirable Effects Pharmacological Properties Interactions Posology Contraindications Excipients Storage precautions
{printer} Print SmPC information
1. Name of the medicinal product

Sterile Concentrate for Cardioplegia Infusion

2. Qualitative and quantitative composition

Each ml of solution contains 0.163g Magnesium Chloride Hexahydrate Ph Eur, 0.060g Potassium Chloride Ph Eur and 0.014g Procaine Hydrochloride Ph Eur.

3. Pharmaceutical form

Sterile aqueous solution

4. Clinical particulars
4.1 Therapeutic indications

Sterile Concentrate for Cardioplegia Infusion is used during heart surgery to induce cardioplegia.

Solution for infusion into the coronary arteries during cardiopulmonary bypass to induce cardioplegia.

4.2 Posology and method of administration

A sterile aqueous solution for dilution. 20 ml are diluted with 1 litre of Compound Sodium Chloride Injection BPC, immediately before use.

4.3 Contraindications

Hypersensitivity to procaine

4.4 Special warnings and precautions for use

The contents of one (20 ml) ampoule must be diluted with 1 litre of Compound Sodium Chloride Injection BPC, immediately before use.

4.5 Interaction with other medicinal products and other forms of interaction

None stated.

4.6 Pregnancy and lactation

None stated

4.7 Effects on ability to drive and use machines

None stated.

4.8 Undesirable effects

None stated.

4.9 Overdose

Appropriate supportive measures should be taken.

Apnoea: It may be necessary to apply artificial respiration

For circulatory depression: Give a vasopressor and intravenous fluids.

For seizures: Give oxygen and intravenous diazepam.

For methaemoglobinaemia: Give oxygen and methylene blue

5. Pharmacological properties
5.1 Pharmacodynamic properties

At the concentration produced after diluting the product, magnesium chloride increases conduction time and the PR and QRS intervals are lengthened. Elevated potassium levels have significant effects on electrical activity in the heart. The T waves become increased in height, the PR interval lengthens and the P wave disappears as potassium concentration increases. The Procaine hydrochloride acts as a local anaesthetic. The primary site of action for procaine is the myocardium, resulting in a decrease in electrical excitability, conduction rate and force of contraction.

5.2 Pharmacokinetic properties

Procaine hydrochloride is almost completely metabolised with only about 2% excreted unchanged in the urine. The half life is less than one minute.

5.3 Preclinical safety data

Acute toxicity data for procaine hydrochloride indicates an LD50 of 200 mg/kg following oral administration in the Rat. There are no other additional preclinical safety data that would be of significance to the prescriber.

6. Pharmaceutical particulars
6.1 List of excipients

Disodium Edetate BP

Sodium Hydroxide

Water for Injections BP

6.2 Incompatibilities

None stated.

6.3 Shelf life

3 years (36 month)

6.4 Special precautions for storage

Do not store above 25° C.

Protect from light

6.5 Nature and contents of container

Clear colourless Ph Eur type I glass ampoules containing 20 ml of solution.

The ampoules are packed in cartons of 10.

6.6 Special precautions for disposal and other handling

None stated

7. Marketing authorisation holder

Macarthy's Laboratories Ltd

T/a Martindale Pharmaceuticals

Bampton Road,

Romford

RM3 8UG

8. Marketing authorisation number(s)

PL 01883/0012

9. Date of first authorisation/renewal of the authorisation

6 April 1982

10. Date of revision of the text

24/06/2013

Martindale Pharma, an Ethypharm Group Company
Company image
Address
Jupiter House, Mercury Park, Wooburn Green, High Wycombe, Buckinghamshire, HP10 0HH, UK
WWW
http://ethypharm.co.uk/
Telephone
+44 (0) 1277 266 600
Medical Information e-mail
[email protected]